DEA’s Schedule III Cannabis Order: A Free-For-All for Telehealth Platforms, or the Perfect Setup for the Entire Industry?

Cannabis ETFs: Regulatory Momentum Returns Focus

Cannabis stocks have seen renewed investor interest as federal policy momentum improves. The most important recent development was the placement of FDA-approved marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III under the Controlled Substances Act. Schedule III drugs are considered to have a lower abuse potential than Schedule I or [...] The post Cannabis ETFs: Regulatory Momentum Returns Focus appe…

Cannabis Sector Re-Rating Is Imminent

The cannabis industry is entering a new era. In this episode of Trade To Black, presented by Flowhub, host Shadd Dales and Anthony Varrell sit down with Seth Yakatan to break down the seismic shift underway following the DOJ’s final ruling on cannabis rescheduling from Schedule I to Schedule III. We’ll unpack what this landmark decision means for the re-rating of cannabis equities, operator margins, and the broader capital markets landscape. We …

DEA’s Schedule III Cannabis Order: A Free-For-All for Telehealth Platforms, or the Perfect Setup for the Entire Industry?

As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling in. In this guest post from regular Business of Cannabis contributor and cannabis policy analyst Deb Tharp, she argues that the Blanche order is not the clean win it appears. For operators, telehealth platforms and dispensaries rushing to claim the benefits of Schedule III, she has a warning: the sam…